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Abstract  
Multiple sclerosis (MS) is an autoimmune disorder characterized by the central nervous system 
(CNS) infiltration of myelin-specific pathogenic T cells followed by brain inflammation in 
association with demyelination. Similarly, experimental autoimmune encephalomyelitis (EAE), 
the animal model of MS, also exhibits increased CNS infiltration of pathogenic T cells, including 
Th1 and Th17, leading to detrimental effects of neuroinflammation and demyelination. We 
previously reported that 3H-1,2-dithiole-3-thione (D3T), the structurally-simplest of the sulfur-
containing dithiolethiones, exerted a promising therapeutic effect in EAE. In the current study 
we report that 5-Amino-3-thioxo-3H-(1,2)dithiole-4-carboxylic acid ethyl ester (ACDT), a 
substituted derivative of D3T, exhibits anti-inflammatory properties in EAE. ACDT, 
administered post immunization, delayed disease onset and reduced disease severity in chronic 
C57BL/6 EAE, and ACDT, administered during disease remission, suppressed disease relapse in 
relapsing-remitting SJL/J EAE. Further analysis of the cellular and molecular mechanisms 
underlying the protective effects of ACDT in EAE revealed that ACDT inhibited pathogenic T 
cell infiltration, suppressed microglia activation, repressed neurotoxic A1 astrocyte generation, 
lessened blood-brain barrier disruption, and diminished MMP3/9 production in the CNS of EAE. 
In summary, we demonstrate that ACDT suppresses neuroinflammation and ameliorates disease 
severity in EAE through multiple cellular mechanisms. Our findings suggest the potential of 
developing ACDT as a novel therapeutic agent for the treatment of MS/EAE.    
 
Keywords: MS/EAE; Microglia; Th1/Th17; A1 astrocyte; ACDT; Neuroinflammation; Blood-
brain barrier  
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1. Introduction 
Multiple sclerosis (MS) is an autoimmune disorder characterized by the CNS infiltration of 
myelin-specific pathogenic T cells and subsequent brain inflammation in association with myelin 
sheath deterioration (Fletcher et al., 2010; Kurschus, 2015; Yadav et al., 2015). Experimental 
autoimmune encephalomyelitis (EAE) is a commonly used animal model to study MS. Several T 
cell subsets, including CD4
+ 
T cell lineages of Th1 and Th17, CD8
+
 T cells, and IL-17-
producting γδT cells, are essential for the pathogenesis of EAE (Camara et al., 2013; Codarri et 
al., 2011; Grifka-Walk et al., 2015; Jager et al., 2009; McWilliams et al., 2015; Paul et al., 2015). 
In addition, antigen presenting cells such as peripheral dendritic cells and CNS microglial cells 
have been shown to play a pivotal role in the promotion of differentiation and reactivation of 
pathogenic T cells, respectively (Blink et al., 2009; Croxford et al., 2015).  
In our previous study, we demonstrated the amelioration of EAE by the agent 3H-1,2-dithiole-3-
thione (D3T) (Kuo et al., 2016). The promising in vivo activity of D3T, the structurally-simplest 
of the sulfur-containing dithiolethiones, is a composite of its physicochemical, pharmacokinetic, 
and pharmacodynamic properties. Further improvement in the activity of D3T can be made by 
optimizing these properties through structural modifications.  As such, we aimed to determine 
the influence of modifications of D3T structure on EAE activity. We sought a molecule that 
retains the dithiolethione pharmacophore, but has functional groups that are easily modified.  
Our search identified compound 5-Amino-3-thioxo-3H-(1,2)dithiole-4-carboxylic acid ethyl 
ester (ACDT), a dithiolethione with ethyl ester and primary amine functional groups 
(Supplemental Fig. 1). We, therefore, decided to investigate the therapeutic efficacy of ACDT in 
EAE.  
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In the present study, we report that ACDT exerts anti-inflammatory effects on the amelioration 
of neuroinflammation in EAE. Our results showed ACDT, administered post immunization, 
delayed disease onset and reduced disease severity in chronic C57BL/6 EAE, and ACDT, 
administered during disease remission, effectively suppressed disease relapse in relapsing-
remitting SJL/J EAE. Further investigation of cellular and molecular mechanisms underlying the 
protective effect of ACDT in EAE revealed that ACDT suppressed CNS infiltration of 
pathogenic T cells, including Th1 and Th17 cells. In addition, ACDT exhibited a suppressive 
effect on microglia (MG) activation in LPS-stimulated primary MG and in the CNS of EAE. 
Furthermore, through analyzing neuroinflammatory status in the CNS of vehicle- and ACDT-
treated EAE mice, we found that several key inflammatory mediators related to EAE 
pathogenesis, including TNFα, osteopontin, ICAM-1, CD40, myeloperoxidase, CCL5, and 
CCL6, were suppressed by ACDT. The modulatory effect on the generation of A1 astrocytes, 
which have been shown to exert a neurotoxic effect (Liddelow et al., 2017), was also observed in 
the CNS of ACDT-treated EAE mice compared to that in vehicle-treated EAE controls. 
Importantly, ACDT treatment lessened blood-brain barrier (BBB) disruption, and that is 
associated with suppressed MMP3 and MMP9 production in the spinal cord of ACDT-treated 
EAE mice. In summary, we demonstrate that ACDT alleviates neuroinflammation in EAE 
through inhibiting pathogenic T cell infiltration, suppressing MG activation, and lessening BBB 
disruption in the CNS of EAE. Our findings suggest that ACDT could be developed as a 
potential therapeutic agent for the treatment of MS/EAE.    
 
2. Material and Methods 
2.1 Animals 
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C57BL/6 and SJL/J mice, purchased from The Jackson Laboratory (Bar Harbor, ME), were used 
in this study. Mice were bred with free accessed food and water, and housed in rooms with 
controlled temperature, humidity, and 12∶12 hour light∶dark cycle. All animal studies procedures 
were approved by the Purdue University Animal Care and Use Committee (PACUC). 
 
2.2 Reagents 
5-Amino-3-thioxo-3H-(1,2)dithiole-4-carboxylic acid ethyl ester (ACDT) was purchased from 
Oakwood Chemicals (West Columbia, SC). Complete Freund’s adjuvant (CFA), Solutol® HS 15, 
Evans blue, collagenase, deoxyribonuclease I (DNase I), phorbol myristate acetate (PMA), 
ionomycin, paraformaldehyde, hematoxylin, eosin, cresyl violet, and  luxol fast blue (LFB) were 
purchased from Sigma-Aldrich (St. Louis, MO). Antibodies for FACS analysis, including Alexa 
Fluor 488 anti-mouse CD4 (clone: RM4-5), APC anti-mouse IL-17A (clone: TC11-18H10.1), 
PE/Cy7 anti-mouse IFNγ (clone: XMG1.2), APC anti-mouse CD45 (clone: 30-F11), PE anti-
mouse CD11b (clone: M1/70), APC anti-mouse CD40 (clone: 3/23), PE anti-mouse CD80 
(clone: 16-10A1), PE/Cy7 anti-mouse CD80 (clone: 16-10A1), PE anti-mouse CD86 (clone: GL-
1), and PE/Cy7 anti-mouse CD86 (clone: GL-1) were purchased from BioLegend (San Diego, 
CA). Antibodies for western blots, including anti-MMP9 (clone: L51/82) and MMP3 (clone: 
M4405F10) and reagents for intracellular staining, including Brefeldin A solution, fixation 
buffer, and permeabilization wash buffer, were purchased from BioLegend (San Diego, CA). 
Mycobacterium tuberculosis H37 RA and antibodies of β-actin (clone: C4/actin) and HRP goat 
anti-mouse IgG for western blots were purchased from BD (Sparks, MD). Pertussis toxin was 
purchased from List Biological Labs (Campbell, CA). Percoll was purchased from GE 
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Healthcare Life Sciences (Pittsburgh, PA). Metaphosphoric acid was purchased from Alfa Aesar 
(Tewksbury, MA).  
 
2.3 EAE Induction 
C57BL/6 mice were immunized with MOG35-55 and SJL/J mice were immunized with PLP139-151 
to induce chronic and relapsing-remitting EAE, respectively. Disease induction was conducted as 
previously described (Kuo et al., 2016). In brief, 7-9 weeks old female mice were 
subcutaneously injected with an emulsion of 200μg MOG35-55 peptide (C57BL/6 model) or 
100μg PLP139-151 (SJL/J model) in CFA containing Mycobacterium tuberculosis H37 RA (final 
concentration 2 mg/ml) on day 0, and followed by intraperitoneal (i.p.) administration of 200ng 
pertussis toxin in PBS on day 0 and day 2. EAE mice were then randomly grouped into two 
groups. One group was i.p administered with vehicle (0.5ml 5% Solutol HS 15 / 0.9% saline / 
DMSO) and the other group was administered with ACDT (0.5ml 5% Solutol HS 15 / 0.9% 
saline / 20mg/kg ACDT dissolved in DMSO). The clinical scores of vehicle- and ACDT-treated 
EAE mice were evaluated based on the following criteria; 0: normal mouse, no overt signs of 
disease; 1: limp tail or hind limb weakness; 2: limp tail and hind limb weakness; 3: partial hind 
limb paralysis; 4: complete hind limb paralysis; and 5: moribund state. Animals with clinical 
scores of 5 were euthanized. 
 
2.4 Brain and Spinal Cord Tissue Processing  
EAE mice were anesthetized and perfused with ice-cold PBS. The brain and spinal cord were 
then harvested and homogenized. The brain tissues were homogenized with HBSS buffer only, 
and the spinal cord tissues were homogenized with HBSS buffer, containing collagenase and 
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DNase I, followed by 37°C incubation for 45 minutes. Homogenized brain and spinal cord tissue 
samples were then filtered through 70-μm nylon cell strainers. After centrifugation, cells 
prepared from brain and spinal cord tissues were subjected to mononuclear cell isolation or RNA 
extraction. In addition, cells prepared from spinal cord tissues were subjected to cytokine array 
and western blots.  
 
2.5 Isolation of Mononuclear Cells from Brain and Spinal Cord Tissues  
Mononuclear cell isolation was processed as previously described (Kuo et al., 2016). Cells 
prepared from brain and spinal cord tissues were then resuspended in 8ml 30% Percoll and 
underlayered with 4ml 70% Percoll followed by centrifugation for 25 minutes at 1000g at room 
temperature (RT). The mononuclear cells were isolated from the interface between 30% and 70% 
Percoll.   
 
2.6 FACS Analysis for Intracellular Cytokines and Surface Markers 
Mononuclear cells isolated from the spinal cord and brain of C57BL/6 EAE animals were 
stimulated with PMA (50ng/ml) and ionomycin (750ng/ml) in the presence of Brefeldin A 
solution (1μl/ml).  5 hours later, cells were then fixed and permeabilized followed by 
intracellular staining with antibodies of Alexa Fluor 488 anti-mouse CD4 antibody, PE/Cy7 anti-
mouse IFNγ, and APC anti-mouse IL-17. IFNγ- and IL-17-expressing CD4+ T cells were then 
determined by FACS analysis. For MG surface marker analysis, the isolated mononuclear cells 
were stained with PE anti-mouse CD11b and APC anti-mouse CD45 with PE/Cy7 anti-mouse 
CD80 or PE/Cy7 anti-mouse CD86, and primary MG were stained with PE anti-mouse CD80, 
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PE/Cy7 anti-mouse CD86, and APC anti-mouse CD40, followed by FACS analysis (BD 
FACSVerse). 
 
2.7 Cytokine Array 
The Proteome Profiler
TM
 Array - Mouse XL Cytokine Array Kit (R&D Systems, ARY028) was 
used to determine the relative expression level of cytokines and chemokines in the spinal cord of 
EAE mice. Experiments were conducted according to the manufacturer's instructions. Cells 
prepared from spinal cord tissues were lysed in RIPA buffer [50mM Tris-HCl (pH8.0), 150mM 
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.3% SDS, 1mM PMSF, and 1X protease inhibitor 
cocktail]. Protein concentration was detected by PierceTM BCA Protein Assay Kit (Thermo 
Fisher Scientific). 200µg spinal cord protein was incubated with array membrane for overnight at 
4°C on a rocking platform shaker. After incubation, the membrane was washed and incubated 
with the Detection Antibody Cocktail for 1 hour at RT. The membrane was then washed and 
incubated with 1X Streptavidin-HRP for 30 minutes at RT followed by washing and incubation 
with Chemi Reagent Mix. Signal dots appeared on the membrane were then detected by X-ray 
film (FUJIFILM Super RX-N). The fold change of signal dots representing cytokine and 
chemokine expression was measured and determined by using protein array analyzer running 
under Image J (National Institutes of Health). 
 
2.8 Measurement of glutathione levels in the Brain and Spinal Cord of EAE 
Brain and spinal cord tissues collected from EAE mice were subjected to glutathione (GSH) 
assay. The total GSH level was measured by using Glutathione (GSSG/GSH) Detection Kit 
(Enzo Life Sciences, ADI-900-160). The brain and spinal cord tissues were homogenized in ice-
  
8 
 
cold 5% (w/v) metaphosphoric acid (20ml/g tissue). Following centrifugation, supernatants were 
subjected to absorbance reading (405 nm) by BioTek Synergy HT microplate reader (Winooski, 
VT) to determine GSH levels according to manufacturer’s instruction. 
 
2.9 Western Blot Analysis  
Cells prepared from spinal cord tissues were lysed in RIPA buffer [50mM Tris-HCl (pH8.0), 
150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.3% SDS, 1mM PMSF, and 1X protease 
inhibitor cocktail]. Protein concentration was detected by Pierce
TM
 BCA Protein Assay Kit 
(Thermo Fisher Scientific). Tissue Protein samples were separated on 10% SDS-PAGE and then 
transferred to polyvinylidene difluoride (PVDF) membranes (Millipore). Blots were then 
incubated with MMP9, MMP3, or β-actin antibody. Protein signals were detected by using 
Immobilon
TM
 Western Chemiluminescent HRP Substrate (Millipore) and X-ray film. The 
quantification of protein signals was measured by using Image J software. 
 
2.10 Primary MG Cell Culture 
Primary MG were generated as previously described (Kuo et al., 2017). In brief, cerebral cortical 
cells from 1-2 days old neonatal mice were plated in 75-cm
2
 culture flasks in Dulbecco Modified 
Eagle Medium/F12 (DMEM/F12) (HyClone
TM
) supplemented with 10% heat-inactivated FBS, 
containing 2mM glutamine and 1X antibiotic/antimycotic (complete medium). On day 3 and 6 
after plating, medium was removed and replenished with fresh complete medium containing 10 
ng/ml GM-CSF. MG were harvested at Day 13 or 14 by shaking the flasks at 350 rpm for 30 
minutes at 37°C. Harvested cells were then seeded in the tissue culture wells. After overnight 
resting, cells were stimulated with LPS for 24h to induce surface expression of CD40, CD80, and 
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CD86, or for 1.5h and 3h to induce inflammatory gene expression based on our previous study 
(Kuo et al., 2017). 
 
2.11 Real-time RT-PCR 
Primary MG and cells prepared from brain and spinal cord tissues were subjected to RNA 
extraction followed by cDNA synthesis. Expression of Il-1β, Il-12p35, Il-12p40, Il-23p19, Il-6, 
Gm-csf, Il-1α, Tnfα, Gata1, H2-D1, and Serping1 were detected by real-time RT-PCR as 
previous described (Yen et al., 2008). The primers used were Il-1β: sense 5’-
CCCTGCAGCTGGAGAGTGTGGA-3’ and antisense 5’-TGTGCTCT GCTTGGAGGTGCTG-
3’; Il-12p35: sense 5’-CTGTGCCTTGGTAGCATCTATG -3’ and anti-sense 5’-
GCAGAGTCTCGCCATTATGATTC-3’; Il-12p40: sense 5’-TGGTTTGCCATCGTTT 
TGCTG-3’ and antisense 5’-ACAGGTGAGGTTCACTGTTTCT-3’; Il-23p19: sense 5’-TGCTG 
GATTGCAGAGCAGTAA-3’ and anti-sense 5’-GCATGCAGAGATTCCGAGAGA-3’; Il-6: 
5’-TCCTCTCTGCAAGAGACTTCCATCC-3’ and anti-sense 5’-
GGGAAGGCCGTGGTTGTCA CC-3’; Gm-csf: sense 5’-ATGCCTGTCACGTTGAATGAAG-
3’ and anti-sense 5’-GCGGGTCT GCACACATGTTA-3’; Il-1α: sense 5’- 
CGCTTGAGTCGGCAAAGAAAT-3’ and antisense 5’- CTTCCCGTTGCTTGACGTTG-3’; 
Tnfα: sense 5’-ATGGCCTCCCTCTCATCAGT-3’ and antisense 5’-
CTTGGTGGTTTGCTACGACG-3’; Gata1: sense 5’- GTGAACAGCATGAGGGG TTT-3’ and 
antisense 5’- GTTTTGTTGCCTCTGGGTGT-3’; H2-D1: sense 5’-TCCGAGATTGT 
AAAGCGTGAAGA-3’ and anti-sense 5’- ACAGGGCAGTGCAGGGATAG-3’; Serping1 
sense 5’- ACAGCCCCCTCTGAATTCTT-3’ and antisense 5’-
GGATGCTCTCCAAGTTGCTC-3’.  
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2.12 Evans Blue BBB Permeability Assay 
Evans blue extravasation of CNS tissues of EAE was determined as previously described with 
modifications (Fairless et al., 2012; Lee et al., 2012). Mice were intravenously (i.v.) 
administrated 4ml/kg 2% (w/v) Evans blue dye. After 2 hours circulation, mice were 
anesthetized and perfused with PBS. The brain and spinal cord of EAE mice were then carefully 
dissected to assess Evans blue leakage.  
 
2.13 Histopathology 
EAE mice were sacrificed and perfused with PBS. The spinal cord was then removed from spinal 
columns, and the lumbar region of spinal cord was then separated and fixed in 4% 
paraformaldehyde at 4°C for overnight. Fixed tissues were embedded in paraffin for sectioning. 
Serial 8µm sections were cut on a microtome (Leica RM2155). Cross sections were used for 
hematoxylin and eosin (H&E) or LFB/cresyl violet staining. Stained spinal cord slides were 
examined and imaged under magnification (microscope: BX53, Olympus; camera: EXi Aqua, Q 
Imaging). Image J was used to quantify the area of cell infiltration and the percentage of 
demyelination by an experimenter blinded to experimental groups. 
 
2.14 Statistical Analysis 
Experimental results are given as mean ± SEM. Comparisons between groups were done by 
using the Mann-Whitney U test, unpaired t test, or one-way ANOVA test. Statistical significance 
was determined as p values ≤ 0.05. All statistical analysis was performed by using GraphPad 
Prism 5 software (La Jolla, CA).  
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3. Results 
3.1 ACDT ameliorates disease severity in chronic and relapsing-remitting EAE 
To determine whether ACDT exerts a therapeutic potential in EAE, C57BL/6 mice immunized 
with MOG35-55 were treated with ACDT every day starting from day 1 post immunization, and 
the clinical score of vehicle- and ACDT-treated EAE mice was followed for a period of 30 days. 
Our results showed that ACDT treatment not only delayed disease onset but also reduced disease 
severity in EAE, with the maximum disease score of 2.2±0.3 compared to that of 4.1±0.2 in 
vehicle-treated EAE controls (Fig. 1A and Table). When comparing the cumulative score, 
ACDT-treated EAE mice had a much lower cumulative disease score of 26.6±4.6 compared to 
that of 64.3±2.8 in vehicle-treated EAE controls (Fig. 1A Table).  
We then explored the therapeutic potential of ACDT on the suppression of disease relapse in 
EAE. Relapsing-remitting EAE was induced in SJL/J mice, and EAE mice were administered 
with vehicle or ACDT during disease remission (disease score below 1.5). ACDT treatment 
suppressed disease relapse in EAE, with the maximum disease score of post treatment only 
reaching 1.4±0.2, whereas vehicle-treated EAE controls developed disease relapse following 
remission, with the maximum disease score of post treatment reaching 3.0±0.3 (Fig. 1B and 
Table). When comparing the cumulative score of post treatment, ACDT-treated EAE mice had a 
much lower cumulative score of 12.6±1.9 compared to vehicle-treated EAE mice of 30.2±2.7 
(Fig. 1B Table). Taken altogether, these results demonstrate that ACDT confers protection 
against EAE through ameliorating disease severity and suppressing disease relapse in EAE.   
 
3.2 ACDT suppresses CNS infiltration of encephalitogenic Th1 and Th17 cells in EAE 
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The CNS infiltration of encephalitogenic Th1 and Th17 cells plays a pivotal role in the 
pathogenesis of EAE (Jager et al., 2009; McWilliams et al., 2015). To investigate whether 
ACDT suppresses encephalitogenic CD4
+
 T cell infiltration of CNS, mononuclear cells were 
isolated from the brain and spinal cord of vehicle- and ACDT-treated EAE mice at day 13-14 
post immunization, and the isolated cells were then subjected to FACS analysis of total CD4
+
 T 
cells and CD4
+
 T cells expressing IFNγ (Th1) and IL-17 (Th17). We observed a significant 
increase of infiltrating CD4
+
 T cells in the brain and spinal cord of vehicle-treated EAE mice 
(Fig. 2A), and those CD4
+
 T cells positively expressed IFNγ (Fig. 2B) or IL-17 (Fig. 2C). In 
contrast, the number of infiltrating CD4
+
 T cells was largely reduced in the CNS of ACDT-
treated EAE mice compared to that in vehicle-treated EAE controls, and that is associated with 
decreased infiltration of encephalitogenic Th1 and Th17 cells (Fig. 2). Collectively, these results 
suggest that ACDT-conferred protection in EAE might be mediated through the suppression of 
CNS infiltration of encephalitogenic Th1 and Th17 cells.  
 
3.3 ACDT suppresses MG activation 
MG are the major CNS resident immune cells and function as antigen presenting cells to 
reactivate pathogenic T cells in lesion sites, thereby exacerbating the disease by epitope 
spreading (McMahon et al., 2005; Tompkins et al., 2002). MG activation leads to increased 
secretion of diverse cytokines and enhanced expression of surface maturation markers CD40, 
CD80, and CD86. To investigate whether ACDT exerts a suppressive effect on MG activation, 
we cultured primary MG and activated MG with LPS in the presence or absence of ACDT. LPS 
upregulated surface expression of CD40, CD80, and CD86, whereas ACDT suppressed LPS-
induced CD40, CD80, and CD86 upregulation (Fig. 3A). Moreover, LPS upregulated 
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inflammatory cytokine expression, including IL-23p19, IL-1β, and IL-6 required for Th17 
differentiation and reactivation, and IL-12p35 and IL-12p40 required for Th1 differentiation and 
reactivation. In contrast, ACDT suppressed LPS-induced IL-12p35, IL-12p40, IL-1β, IL-6, and 
IL-23p19 expression (Fig. 3B). GM-CSF, which was shown to promote neuroinflammation in 
EAE (El-Behi et al., 2011; Shiomi et al., 2015), was also upregulated in MG activated with LPS, 
but downregulated in MG activated with LPS in the presence of ACDT (Fig 3B).  
To further investigate whether ACDT modulates MG activation in vivo, EAE was induced and 
mononuclear cells were isolated from the spinal cord and brain of vehicle- and ACDT-treated 
EAE mice at day 13-14 post immunization. The isolated cells were then subjected to CD45, 
CD11b, CD80, and CD86 staining followed by FACS analysis. MG were determined based on 
their positive expression of CD11b and intermediated expression of CD45. Although there was 
no significant difference of CD86 expression on the surface of CD45
int
CD11b
+
 MG isolated from 
the spinal cord and brain of vehicle- and ACDT-treated EAE mice, CD80 expression was 
significantly reduced on the surface of CD45
int
CD11b
+
 MG isolated from the spinal cord and 
brain of ACDT-treated EAE mice compared to that in vehicle-treated EAE controls (Fig. 3C). 
Altogether, these results suggest that ACDT possesses a suppressive effect on MG activation in 
vitro as well as partially in vivo.   
 
3.4 ACDT lessens neuroinflammation in EAE 
To further investigate whether ACDT-mediated suppression of pathogenic T cell infiltration and 
MG activation could lead to the alleviation of neuroinflammation in EAE, the spinal cord 
harvested from vehicle- and ACDT-treated EAE mice was subjected to cytokine array to 
determine the expression of inflammatory mediators. We found that chemokines, related to the 
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recruitment of inflammatory immune cells, including CCL5, CCL6, CCL17, and CXCL10, were 
expressed in the spinal cord of EAE mice, but  their expression was suppressed in the spinal cord 
of ACDT-treated EAE mice (Fig. 4A). In addition, inflammatory mediators that are associated 
with pathogenesis of EAE, such as osteopontin, CD40, ICAM-1, and myeloperoxidase, were also 
expressed in the spinal cord of EAE, but suppressed in the spinal cord of ACDT-treated EAE 
mice (Fig. 4A).  
A recent study shows that IL-1α, TNFα, and C1q, produced by activated MG, induce neurotoxic 
reactive astrocytes that are named “A1 astrocytes”. Importantly, these neurotoxic A1 astrocytes 
are also present in post-mortem brain tissues of MS patients (Liddelow et al., 2017). In our array 
results, we found that IL-1α was expressed in the spinal cord of vehicle-treated EAE controls, 
but suppressed in the spinal cord of ACDT-treated EAE mice. We speculated that ACDT might 
regulate neurotoxic A1 astrocytes in the CNS of EAE through modulating the expression of 
inflammatory molecules required for A1 astrocyte generation. We then measured IL-1α, TNFα, 
and C1q expression in the CNS of vehicle- and ACDT-treated EAE mice. Although we did not 
detect the expression of C1q in the CNS of EAE mice (data not shown), the expression of TNFα 
and IL-1α was largely suppressed in the spinal cord and brain of ACDT-treated EAE mice 
compared to those in vehicle-treated EAE controls (Fig 4B). Subsequently, we determined the 
levels of A1 astrocytes in the spinal cord and brain of vehicle- and ACDT-treated EAE mice by 
measuring A1 astrocyte specific genes, including Ggta1, H2-D1, and Serping1. The expression 
of Ggta1, H2-D1, and Serping1 was suppressed in the CNS of ACDT-treated EAE mice 
compared to that in vehicle-treated EAE controls (Fig. 4C). Taken altogether, these results 
demonstrate that ACDT lessens neuroinflammation and potentially suppresses neurotoxic A1 
astrocyte generation in EAE.  
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3.5 ACDT lessens BBB disruption and alleviates spinal cord pathology in EAE  
To determine whether ACDT lessens EAE-induced BBB disruption, during the peak of disease 
vehicle- and ACDT-treated EAE mice were subjected to Evans Blue injection followed by the 
brain and spinal cord tissue isolation to assess BBB integrity. Evans blue leakage was clearly 
observed in the CNS especially in the spinal cord of vehicle-treated EAE controls, indicating a 
compromised BBB integrity. On the other hand, the leakage of Evans blue was significantly 
reduced in the spinal cord and brain of ACDT-treated EAE mice, suggesting a well preserved 
BBB integrity in ACDT-treated EAE mice (Fig. 5A). Both MMP3 and MMP9 play a detrimental 
role in BBB disruption and breakdown in several neurodegenerative diseases (Fanjul-Fernandez 
et al., 2010; Gerwien et al., 2016; Kim et al., 2011; Konnecke et al., 2013), we thought to 
determine whether the beneficial effect of ACDT on BBB integrity in EAE is mediated through 
its regulatory effect on MMP3 and MMP9 production. We measured MMP3 and MMP9 
expression in the spinal cord of vehicle- and ACDT-treated EAE mice, and found MMP3 and 
MMP9 were highly expressed in the spinal cord of vehicle-treated EAE controls. Conversely, the 
expression of MMP3 and MMP9 was largely suppressed in the spinal cord of ACDT-treated 
EAE mice (Fig 5B).  
We further examined the histopathological features of spinal cord in vehicle- and ACDT-treated 
EAE mice. The spinal cord harvested from EAE mice was subjected to H&E and LFB/cresyl 
violet staining to assess cell infiltration and demyelination, respectively. We observed a 
significant increase of infiltrating inflammatory cells and a moderate level of demyelination in 
the spinal cord of vehicle-treated EAE controls. In contrast, the histopathology of cell infiltration 
and demyelination was alleviated in the spinal cord of ACDT-treated EAE mice (Fig. 5C and D). 
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Altogether, these results demonstrate that ACDT lessens BBB disruption, suppresses MMP3 and 
MMP9 production, inhibits inflammatory cell infiltration, and alleviates demyelination in the 
spinal cord of EAE.   
 
3.6 ACDT enhances GSH levels in the CNS of EAE  
The inflammatory process in EAE is associated with increased production of reactive oxygen 
species and reduced production of redox active compounds, such as GSH, in the CNS (Choi et 
al., 2015; Ljubisavljevic et al., 2012; Mohamed et al., 2003; Morales Pantoja et al., 2016; Ruuls 
et al., 1995). Our group has previously demonstrated that ACDT strongly induced the production 
of GSH in SH-SY5Y cells (Brown et al., 2016). To assess whether ACDT induces GSH 
production in the CNS to modulate neuroinflammation in EAE, the spinal cord and brain were 
harvested from vehicle- and ACDT-treated EAE mice and subjected to GSH analysis. We found 
that GSH levels were higher in the brain and spinal cord of ACDT-treated EAE mice than those 
in vehicle-treated EAE controls (Fig. 6), suggesting that the induction of GSH by ACDT might 
contribute to its suppressive effect on neuroinflammation in EAE.  
 
4. Discussion  
Dithiolethiones have well-demonstrated protective effects in a number of neurodegenerative and 
neurological diseases, including Alzheimer disease, UV-induced retinal pigment epithelium cell 
injury, stroke, and EAE (Cui et al., 2017; Kuo et al., 2016; Kuo et al., 2017; Li et al., 2016; 
Wang et al., 2017). Our group previously reported the anti-inflammatory properties of D3T, the 
structurally simplest of the dithiolethiones, in EAE (Kuo et al., 2016).  As a continuation of our 
study of D3T, we sought to assess the effect of modifying the dithiolethione core structure on 
  
17 
 
EAE activity. ACDT structurally retains the dithiolethione pharmacophore, but has two versatile 
functional groups (carboxylic acid ethyl ester and primary amine) that are readily amendable for 
future modifications. As the therapeutic effect of ACDT in EAE is unknown, we therefore 
investigated its activity in two well-established EAE models, chronic C57BL/6 EAE and 
relapsing-remitting SJL/J EAE. We observed that in the chronic EAE, ACDT treatment delayed 
disease onset for an average of 4 days compared to controls, minimized maximum disease score 
to the average of 2.2 as opposed to 4.1 for controls, and ameliorated disease severity with 
cumulative score of 26.6 compared to 64.3 for controls. More importantly, in the relapsing-
remitting EAE, ACDT, administered during disease remission, prevented disease relapse, and the 
cumulative score of post treatment significantly reduced to 12.6 compared to 30.2 for controls. 
Based on these findings, we concluded that ACDT exerts a therapeutic effect in chronic and 
relapsing-remitting EAE by ameliorating disease severity and preventing disease progression.  
We further investigated the cellular mechanisms underlying the protective effect of ACDT in 
EAE. The infiltration of pathogenic Th1 and Th17 cells has been shown to play a critical role in 
the pathogenesis of EAE (El-Behi et al., 2011; Jager et al., 2009). ACDT treatment suppressed 
the infiltration of Th1 and Th17 cells in the spinal cord and brain of EAE mice compared to 
those in vehicle-treated EAE controls. In addition, our observation of reduced total infiltrating 
CD4
+
 T cells in the CNS of ACDT-treated EAE mice led us to speculate that ACDT might 
lessen disease-induced BBB disruption. Indeed, we found that EAE mice treated with vehicle 
had a compromised BBB integrity and EAE mice treated with ACDT exhibited a well preserved 
BBB integrity, as the profound leakage of Evans blue was only observed in the spinal cord of 
vehicle-treated EAE controls but not in the spinal cord of ACDT-treated EAE mice. Further 
analysis of the spinal cord of EAE revealed that metalloproteinases MMP3 and MMP9, essential 
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proteases contributing to the cleavage of BBB basement membrane and degradation of tight 
junction proteins (Lakhan et al., 2013; Yang et al., 2007), were largely expressed in the spinal 
cord of vehicle-treated EAE controls but dramatically suppressed in the spinal cord of ACDT-
treated EAE mice. These results correlate with the histopathology of spinal cord in which 
increased cell infiltration and enhanced demyelination were observed in vehicle-treated EAE 
controls but not in ACDT-treated EAE mice. CNS resident cells, including MG and brain 
endothelial cells, and infiltrating inflammatory immune cells are the cell populations, producing 
MMP3 and MMP9 under neuroinflammatory conditions (Amtul et al., 2014; Brkic et al., 2015; 
Yang et al., 2007). Further investigation would be required to dissect which cell types that secret 
MMP3 and MMP9 following EAE are modulated by the treatment of ACDT. 
A recent study shows that activated microglia induce neurotoxic reactive astrocytes in 
neurodegenerative diseases (Liddelow et al., 2017). Cytokines TNFα and IL-1α and complement 
component C1q released by activated microglia promote the generation of reactive astrocytes 
that exert a toxic effect on neurons. These reactive astrocytes were subsequently named as “A1 
astrocytes”. A1 astrocytes are rapidly generated in vivo following CNS injury and present in 
many human neurodegenerative diseases, including Huntington’s disease, Alzheimer’s disease, 
ALS, Parkinson’s disease, and MS (Liddelow et al., 2017). A1 astrocytes express a spectrum of 
signature genes that can be used for screening or detecting these neurotoxic reactive astrocytes in 
the CNS of neurodegenerative diseases. In the present study, we examined whether ACDT-
mediated amelioration of neuroinflammation could lead to reduced A1 astrocyte generation in 
EAE. We observed ACDT inhibited a spectrum of cytokines, chemokines, and inflammatory 
mediators in the CNS of EAE. Importantly, essential cytokines required for the generation of 
neurotoxic A1 astrocytes, including TNFα and IL-1α, were suppressed in the CNS of ACDT-
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treated EAE mice, although we did not detect the expression of C1q in the CNS of EAE. 
Subsequent analysis of A1 astrocytes in the CNS of EAE revealed that ACDT suppressed the 
expression of A1 astrocyte signature genes, including Ggta1, H2-d1, and Serping1. Thus, our 
results demonstrated that ACDT ameliorated neuroinflammation and that might subsequently 
reduce neurotoxic A1 astrocyte generation in EAE. However, a comprehensive study through 
measuring additional A1markers is required to further confirm the suppressive effect of ACDT 
on the generation of A1 astrocytes in the CNS of EAE. Moreover, whether the reduction of A1 
astrocyte generation by ACDT could lead to decreased neuronal injury in EAE would require 
further investigation to reveal potential neuroprotective effects of ACDT in EAE.   
Our previous study demonstrated that D3T, the structurally-simplest dithiolethione, ameliorated 
disease of EAE (Kuo et al., 2016). In the current study, we showed ACDT, a dithiolethione with 
ethyl ester and primary amine functional groups, alleviated disease severity to a similar degree as 
D3T in EAE. These results suggest a potential use of dithiolethiones as novel therapies for 
EAE/MS. As dithiolethiones are known to potently activate Nrf2 (Jia et al., 2008; Tran et al., 
2009), the protective effect of D3T and ACDT in EAE might be mediated through Nrf2 defense 
pathway. Currently, there is only one FDA-approved Nrf2 activator on the market, dimethyl 
fumarate (DMF) (Alroughani et al., 2017). Based on the success of this drug in the clinic, the 
development of further Nrf2 activators is warranted. Additionally, DMF activates Nrf2 via the 
depletion of GSH, which generates oxidative stress (Lehmann et al., 2007; Xie et al., 2015). This 
has the potential effect of inducing cellular injury. In contrast, dithiolethiones activate Nrf2 in a 
process that does not trigger oxidative stress onto the cell (Brown et al., 2014; Giustarini et al., 
2014; Kwak et al., 2003). Thus, dithiolethiones, such as D3T and ACDT, may represent better 
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therapeutic agents for the treatment of EAE/MS through direct activation of the Nrf2 pathway 
without compromising the beneficial effect of GSH. 
 
5. Conclusions 
We reported for the first time that ACDT conferred protection against the autoimmune 
inflammatory disease EAE. We showed ACDT inhibited CNS infiltration of pathogenic CD4
+
 T 
cells, including Th1 and Th17 cells, and ACDT suppressed MG activation through inhibiting the 
expression of surface maturation markers and the production of inflammatory cytokines. In 
addition, ACDT lessened BBB disruption in the spinal cord of EAE through inhibiting MMP3 
and MMP9 production that resulted in a better preserved BBB integrity with decreased CNS 
infiltration of inflammatory immune cells and alleviated demyelination in the spinal cord of EAE. 
In summary, our study demonstrated that ACDT exerts a therapeutic potential for the treatment 
of MS/EAE by targeting several pathological pathways related to the development and 
progression of EAE.    
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Figure Legends 
Fig. 1 ACDT ameliorates disease severity in chronic and relapsing-remitting EAE 
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(A) C57BL/6 mice (n=18/group) immunized with MOG35-55 were administered i.p. with vehicle 
or ACDT (20mg/kg) every day starting from day 1 post immunization. (B) SJL/J mice 
(n=9/group) were immunized with PLP139-151 to induce EAE. Following the first remission and 
before the onset of second relapse, EAE animals were administered i.p. with vehicle or ACDT 
(20mg/kg) every day. The clinical score of EAE animals was followed, and EAE mortality rate, 
onset of disease, maximum score, and cumulative score were assessed. Data represent mean ± SEM. 
Statistical significance was determined as: *p<0.05, **p<0.01, and ***p<0.001 by Mann-Whitney U test.  
 
Fig. 2 ACDT suppresses CNS infiltration of encephalitogenic Th1 and Th17 cells in EAE 
C57BL/6 mice (n=9/group) were subjected to EAE induction followed by i.p. administration 
with vehicle or ACDT (20mg/kg) every day starting from day 1 post immunization. At day 13 or 
14 post immunization, mononuclear cells were isolated from the brain and spinal cord of vehicle- 
and ACDT-treated EAE mice. The cell numbers of total CD4
+
 T cells (A), IFNγ- (B), and IL-17-
expressing CD4
+
 Th cells (C) in the brain and spinal cord were determined by FACS analysis. 
Isotype controls (ISO) were used to determine cells positive for surface expression of CD4 (A) 
and CD4
+
 T cells positive for intracellular expression of IFNγ (B) or IL-17 (C). Data represent 
mean ± SEM. Statistical significance was determined as: ***p<0.001 by unpaired t test.  
 
Fig. 3 ACDT suppresses MG activation 
Primary MG were left untreated (medium) or pretreated with vehicle or ACDT 100µM for 1 
hour followed by LPS (100ng/ml) stimulation. (A) 24 hours after LPS treatment, cells were 
subjected to FACS analysis for surface expression of CD40, CD80, and CD86. Dashed lines 
represent isotype control. (B) 1.5 and 3 hours after LPS treatment, cells were collected and 
subjected to RNA extraction followed by Q-PCR analysis for mRNA expression of IL-23p19, 
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IL-12p35, IL-12p40, IL-1β, IL-6, and GM-CSF. One representative of three independent 
experiments is shown. Statistical significance was determined as: *p<0.05, **p<0.01, and 
***p<0.001 by one way ANOVA with post hoc Bonferroni’s multiple comparison test. (C) 
C57BL/6 mice (n=8/group) were subjected to EAE induction followed by i.p. administration 
with vehicle or ACDT (20mg/kg) every day starting from day 1 post immunization. At day 13 or 
14 post immunization, mononuclear cells were isolated from the brain and spinal cord of vehicle- 
and ACDT-treated EAE mice, and the isolated cells were then stained with antibodies of CD45 
and CD11b with CD80 or CD86 followed by FACS analysis. MG were determined as 
CD45
int
CD11b
+
 cells, and the expression of CD80 and CD86 on the surface of CD45
int
CD11b
+
 
cells was determined. Isotype controls (ISO) were used to determine MG positive for CD80 or 
CD86 expression. Statistical significance was determined as: ***p<0.001 by unpaired t test.  
 
Fig. 4 ACDT lessens neuroinflammation in EAE 
C57BL/6 mice were subjected to EAE induction followed by i.p. administration with vehicle or 
ACDT (20mg/kg) every day starting from day 1 post immunization. (A) At day 13 post 
immunization, the spinal cord of vehicle- and ACDT-treated EAE mice was harvested and 
subjected to cytokine array analysis (n=3/group). (B and C) At day 13 or 14 post immunization, 
the spinal cord and brain of vehicle- and ACDT-treated EAE mice (n=10/group) were harvested 
and subjected to Q-PCR analysis for mRNA expression of IL-1α, TNFα (B), Ggta1, H2-D1, and 
Serping1 (C). Statistical significance was determined as: *p<0.05, **p<0.01, and ***p<0.001 
by unpaired t test.  
 
Fig. 5 ACDT lessens BBB disruption and alleviates spinal cord pathology in EAE  
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C57BL/6 EAE animals were i.p. administration with vehicle or ACDT (20mg/kg) every day 
starting from day 1 post immunization. At day 13 post immunization, vehicle- and ACDT-treated 
EAE mice (n=5/group) were subjected to i.v. administration of Evans blue. (A) 2 hours after 
Evans blue administration, animals were sacrificed, and the brain and spinal cord of vehicle- and 
ACDT-treated EAE mice were dissected to assess the leakage of Evans blue. (B) The spinal cord 
tissues were homogenized and subjected to western blot analysis of MMP3 and MMP9 
production. (C and D) The lumbar regions of spinal cord tissues were fixed and subjected to 
H&E and LFB/cresyl violet staining to assess cell infiltration and demyelination, respectively. 
The area of cell infiltration and the percentage of demyelination were quantified. Arrow indicates 
cell infiltration (C) and demyelination (D). Statistical significance was determined as: *p<0.05 
and **p<0.01 by Mann-Whitney U test. 
 
Fig. 6 ACDT enhances GSH levels in the CNS of EAE 
C57BL/6 EAE animals were i.p. administration with vehicle or ACDT (20mg/kg) every day 
starting from day 1 post immunization. At day 13 post immunization, the spinal card and brain of 
vehicle- and ACDT-treated EAE animals (n=12/group) were harvested, and GSH levels of spinal 
cord and brain were determined. Statistical significance was determined as: *p<0.05 and 
**p<0.01 by unpaired t test.  
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Highlights 
• Dithiolethione ACDT ameliorates disease severity in both chronic and relapsing-remitting 
EAE. 
• ACDT inhibits the CNS infiltration of pathogenic T cells in EAE.  
• ACDT suppresses MG activation in vitro and in vivo.  
• ACDT alleviates neuroinflammation and reduced neurotoxic A1 astrocyte generation in EAE.  
• ACDT lessens blood-brain barrier disruption and alleviates spinal cord pathology in EAE. 
  
